Medical - Instruments & Supplies
Compare Stocks
2 / 10Stock Comparison
OSUR vs IDXX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
OSUR vs IDXX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Diagnostics & Research |
| Market Cap | $216M | $46.12B |
| Revenue (TTM) | $85M | $4.45B |
| Net Income (TTM) | $-53M | $1.10B |
| Gross Margin | 38.8% | 62.1% |
| Operating Margin | -58.6% | 31.6% |
| Forward P/E | — | 39.9x |
| Total Debt | $13M | $1.08B |
| Cash & Equiv. | $199K | $180M |
OSUR vs IDXX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| OraSure Technologie… (OSUR) | 100 | 20.6 | -79.4% |
| IDEXX Laboratories,… (IDXX) | 100 | 187.5 | +87.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OSUR vs IDXX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OSUR is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.45, Low D/E 3.9%, current ratio 6.58x
IDXX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.35
- Rev growth 10.4%, EPS growth 22.6%, 3Y rev CAGR 8.5%
- 5.7% 10Y total return vs OSUR's -54.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.4% revenue growth vs OSUR's -38.1% | |
| Quality / Margins | 24.6% margin vs OSUR's -61.9% | |
| Stability / Safety | Beta 1.35 vs OSUR's 1.45 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +22.3% vs OSUR's +7.1% | |
| Efficiency (ROA) | 32.6% ROA vs OSUR's -16.6%, ROIC 42.5% vs -20.0% |
OSUR vs IDXX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
OSUR vs IDXX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
IDXX leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IDXX is the larger business by revenue, generating $4.4B annually — 52.2x OSUR's $85M. IDXX is the more profitable business, keeping 24.6% of every revenue dollar as net income compared to OSUR's -61.9%. On growth, IDXX holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $85M | $4.4B |
| EBITDAEarnings before interest/tax | -$45M | $1.5B |
| Net IncomeAfter-tax profit | -$53M | $1.1B |
| Free Cash FlowCash after capex | -$33M | $845M |
| Gross MarginGross profit ÷ Revenue | +38.8% | +62.1% |
| Operating MarginEBIT ÷ Revenue | -58.6% | +31.6% |
| Net MarginNet income ÷ Revenue | -61.9% | +24.6% |
| FCF MarginFCF ÷ Revenue | -38.9% | +19.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -99.9% | +14.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -52.4% | +16.6% |
Valuation Metrics
OSUR leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $216M | $46.1B |
| Enterprise ValueMkt cap + debt − cash | $229M | $47.0B |
| Trailing P/EPrice ÷ TTM EPS | -3.19x | 44.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 39.94x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.10x |
| EV / EBITDAEnterprise value multiple | — | 32.06x |
| Price / SalesMarket cap ÷ Revenue | 1.88x | 10.72x |
| Price / BookPrice ÷ Book value/share | 0.65x | 29.11x |
| Price / FCFMarket cap ÷ FCF | — | 43.78x |
Profitability & Efficiency
IDXX leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
IDXX delivers a 70.9% return on equity — every $100 of shareholder capital generates $71 in annual profit, vs $-19 for OSUR. OSUR carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to IDXX's 0.67x. On the Piotroski fundamental quality scale (0–9), IDXX scores 7/9 vs OSUR's 3/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -19.5% | +70.9% |
| ROA (TTM)Return on assets | -16.6% | +32.6% |
| ROICReturn on invested capital | -20.0% | +42.5% |
| ROCEReturn on capital employed | -16.8% | +61.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 |
| Debt / EquityFinancial leverage | 0.04x | 0.67x |
| Net DebtTotal debt minus cash | $13M | $897M |
| Cash & Equiv.Liquid assets | $199,278 | $180M |
| Total DebtShort + long-term debt | $13M | $1.1B |
| Interest CoverageEBIT ÷ Interest expense | — | 35.55x |
Total Returns (Dividends Reinvested)
IDXX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IDXX five years ago would be worth $10,864 today (with dividends reinvested), compared to $3,083 for OSUR. Over the past 12 months, IDXX leads with a +22.3% total return vs OSUR's +7.1%. The 3-year compound annual growth rate (CAGR) favors IDXX at 6.1% vs OSUR's -24.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +26.1% | -13.5% |
| 1-Year ReturnPast 12 months | +7.1% | +22.3% |
| 3-Year ReturnCumulative with dividends | -57.1% | +19.3% |
| 5-Year ReturnCumulative with dividends | -69.2% | +8.6% |
| 10-Year ReturnCumulative with dividends | -54.8% | +568.9% |
| CAGR (3Y)Annualised 3-year return | -24.6% | +6.1% |
Risk & Volatility
Evenly matched — OSUR and IDXX each lead in 1 of 2 comparable metrics.
Risk & Volatility
IDXX is the less volatile stock with a 1.35 beta — it tends to amplify market swings less than OSUR's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OSUR currently trades 78.5% from its 52-week high vs IDXX's 75.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.45x | 1.35x |
| 52-Week HighHighest price in past year | $3.82 | $769.98 |
| 52-Week LowLowest price in past year | $2.08 | $465.00 |
| % of 52W HighCurrent price vs 52-week peak | +78.5% | +75.2% |
| RSI (14)Momentum oscillator 0–100 | 47.1 | 45.0 |
| Avg Volume (50D)Average daily shares traded | 455K | 531K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates OSUR as "Hold" and IDXX as "Buy". Consensus price targets imply 33.5% upside for IDXX (target: $773) vs 33.3% for OSUR (target: $4).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $4.00 | $773.13 |
| # AnalystsCovering analysts | 13 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +7.0% | +2.6% |
IDXX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). OSUR leads in 1 (Valuation Metrics). 1 tied.
OSUR vs IDXX: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is OSUR or IDXX a better buy right now?
For growth investors, IDEXX Laboratories, Inc.
(IDXX) is the stronger pick with 10. 4% revenue growth year-over-year, versus -38. 1% for OraSure Technologies, Inc. (OSUR). IDEXX Laboratories, Inc. (IDXX) offers the better valuation at 44. 3x trailing P/E (39. 9x forward), making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OSUR or IDXX?
Over the past 5 years, IDEXX Laboratories, Inc.
(IDXX) delivered a total return of +8. 6%, compared to -69. 2% for OraSure Technologies, Inc. (OSUR). Over 10 years, the gap is even starker: IDXX returned +568. 9% versus OSUR's -54. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OSUR or IDXX?
By beta (market sensitivity over 5 years), IDEXX Laboratories, Inc.
(IDXX) is the lower-risk stock at 1. 35β versus OraSure Technologies, Inc. 's 1. 45β — meaning OSUR is approximately 8% more volatile than IDXX relative to the S&P 500. On balance sheet safety, OraSure Technologies, Inc. (OSUR) carries a lower debt/equity ratio of 4% versus 67% for IDEXX Laboratories, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — OSUR or IDXX?
By revenue growth (latest reported year), IDEXX Laboratories, Inc.
(IDXX) is pulling ahead at 10. 4% versus -38. 1% for OraSure Technologies, Inc. (OSUR). On earnings-per-share growth, the picture is similar: IDEXX Laboratories, Inc. grew EPS 22. 6% year-over-year, compared to -261. 5% for OraSure Technologies, Inc.. Over a 3-year CAGR, IDXX leads at 8. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OSUR or IDXX?
IDEXX Laboratories, Inc.
(IDXX) is the more profitable company, earning 24. 6% net margin versus -59. 8% for OraSure Technologies, Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -59. 2% for OSUR. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is OSUR or IDXX more undervalued right now?
Analyst consensus price targets imply the most upside for IDXX: 33.
5% to $773. 13.
07Which pays a better dividend — OSUR or IDXX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is OSUR or IDXX better for a retirement portfolio?
For long-horizon retirement investors, IDEXX Laboratories, Inc.
(IDXX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+568. 9% 10Y return). Both have compounded well over 10 years (IDXX: +568. 9%, OSUR: -54. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between OSUR and IDXX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.